Brookline Capital Management Forecasts YMAB Q1 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at Brookline Capital Management decreased their Q1 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a research note issued to investors on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($0.22) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics' Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.93) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the company posted ($0.02) EPS.

Several other equities analysts have also recently issued reports on the stock. Truist Financial lowered their price objective on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. HC Wainwright reduced their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday, March 21st. Bank of America lowered shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd. Finally, Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $17.40.

Y-mAbs Therapeutics Stock Down 0.7 %

Y-mAbs Therapeutics stock traded down $0.03 during mid-day trading on Friday, hitting $4.17. 53,216 shares of the company's stock traded hands, compared to its average volume of 383,597. Y-mAbs Therapeutics has a one year low of $3.84 and a one year high of $17.78. The company has a market cap of $188.56 million, a PE ratio of -7.72 and a beta of 0.71. The firm has a 50 day moving average price of $4.79 and a 200 day moving average price of $8.01.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 22.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of YMAB. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at $46,000. ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $99,000. Exchange Traded Concepts LLC boosted its stake in Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock valued at $119,000 after buying an additional 13,890 shares in the last quarter. Wells Fargo & Company MN grew its position in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after acquiring an additional 6,131 shares during the period. Finally, SG Americas Securities LLC raised its stake in Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after acquiring an additional 4,163 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.